Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

for
Malignant Neoplasm
Location: Clermont FL, Fargo ND, Sioux Falls SD
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07252739

Phase 2, Recruiting
Active & Responsive

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

for
Advanced Solid Tumor, Metastatic Solid Tumor
Location: Toronto, Grand Rapids MI, Nashville TN, Houston TX,
Sponsor: Ipsen

Sex: All

Age: 18+

Code: NCT07213830

Phase 1, Phase 2, Recruiting
Active & Responsive

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.

for
Metastatic Solid Tumors, Stage 4 Cancer
Location: Rochester MN
Sponsor: New Phase Ltd.

Sex: All

Age: 18+

Code: NCT07224464

Recruiting
Active & Responsive

A Study of DS3610a in Participants With Advanced Solid Tumor

for
Solid Tumors, Metastatic Solid Tumors
Location: Milwaukee WI
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT07159126

Phase 1, Recruiting
Active & Responsive

Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib

for
HER2+ Metastatic Breast Cancer (MBC)
Location: Durham NC
Sponsor: Duke University

Sex: Female

Age: 18+

Code: NCT06983691

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3

for
Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
Location: Baltimore MD, Fairfax VA, Sarasota FL, Atlanta GA,
Sponsor: Myricx Pharma Limited

Sex: All

Age: 18+

Code: NCT07807241

Phase 1, Recruiting
Active & Responsive

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

for
Triple Negative Breast Cancer (TNBC),
Location: Charleston SC
Sponsor: Medical University of South Carolina

Sex: All

Age: 18+

Code: NCT07743190

Phase 2, Recruiting
Active & Responsive

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

for
Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms,
Location: Toms River NJ, Jersey City NJ, Belleville NJ, Newark NJ,
Sponsor: Rutgers, The State University of New Jersey

Sex: All

Age: 18+

Code: NCT07158164

Recruiting
Active & Responsive

Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma

for
Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma,
Location: Memphis TN
Sponsor: St. Jude Children's Research Hospital

Sex: All

Age: 0+

Code: NCT07514819

Recruiting
Active & Responsive

Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)

for
Solid Tumors
Location: Lexington KY
Sponsor: Val Adams

Sex: All

Age: 18 - 70+

Code: NCT07661459

Phase 2, Recruiting
Active & Responsive

Breast Cancer Plasma Adjuvant Intra-operative Treatment (Breast Cancer PAINT)

for
Breast Cancer
Location: Montreal
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Sex: Female

Age: 18+

Code: NCT06222788

Recruiting
Active & Responsive

Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia

for
Hormone Receptor Positive Breast Carcinoma, Postmenopausal,
Location: Philadelphia PA
Sponsor: Thomas Jefferson University

Sex: Female

Age: 18+

Code: NCT07737951

Recruiting
Active & Responsive

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

for
Prostate Cancer Castration-resistant Prostate Cancer,
Location: East Brunswick NJ, Fairfax VA, Grand Rapids MI,
Sponsor: MBrace Therapeutics

Sex: All

Age: 18+

Code: NCT07145255

Phase 1, Phase 2, Recruiting
Active & Responsive

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

for
Anatomic Stage IV Breast Cancer AJCC v8,
Location: Seattle WA
Sponsor: University of Washington

Sex: All

Age: 18+

Code: NCT06502691

Phase 1, Phase 2, Recruiting
Active & Responsive

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

for
Breast Neoplasms, Lung Neoplasms
Location: Providence RI
Sponsor: Brown University

Sex: All

Age: 18+

Code: NCT06974604

Phase 2, Recruiting
Active & Responsive

A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

for
Solid Tumors
Location: New York NY, Baltimore MD, Atlanta GA, Houston TX
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT07492680

Phase 2, Recruiting
Active & Responsive

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

for
Anatomic Stage IV Breast Cancer AJCC v8,
Location: Seattle WA
Sponsor: University of Washington

Sex: All

Age: 18+

Code: NCT07112053

Phase 2, Recruiting
Active & Responsive

Capturing Food Intake in Patients Undergoing Radiation Therapy for Cancer

for
Cancer, Radiation Therapy, Dietary Intake
Location: Minneapolis MN
Sponsor: University of Minnesota

Sex: All

Age: 18+

Code: NCT07682714

Recruiting
Active & Responsive

Fast-Her: Fasting Effects on Breast Cancer Treatment

for
Metastatic Breast Cancer
Location: Minneapolis MN
Sponsor: University of Minnesota

Sex: All

Age: 18+

Code: NCT07624617

Recruiting
Active & Responsive

Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

for
Solid Tumor Cancer
Location: Santa Monica CA
Sponsor: Sarcoma Oncology Research Center, LLC

Sex: All

Age: 18+

Code: NCT07671534

Phase 2, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial